Investigational drug · Phase 3
IBI302
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neovascular Age-related Macular Degeneration, Diabetic Macular Oedema.
Phase 3Last checked: Nov 19, 2026Latest source record: May 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "IBI302"
First trial start
2023
Sep 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI302", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Oedema
Approved drugs for the same conditions: Wet macular degeneration · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI302" as an intervention, largest first.
Innovent Biologics Technology Limited (Shanghai R&D Center)Industry
NCT07275840 · 800 participants (planned) · Start Dec 5, 2025 · Primary completion Aug 30, 2026
Drug: IBI302 8mg dose · For: Neovascular Age-related Macular Degeneration
Sites: Shanghai, China
- A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMDPivotal-lookingActive, not recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05972473 · 600 participants · Start Sep 21, 2023 · Primary completion Feb 28, 2027
Drug: Aflibercept Ophthalmic; IBI302 · For: Neovascular Age-related Macular Degeneration
Sites: Shanghai, China
- Evaluation of IBI302 Injection in nAMD or DMEPivotal-lookingSuspended
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05961007 · 234 participants (planned) · Start Nov 18, 2021 · Primary completion Oct 31, 2023
Drug: Intravitreal injection of IBI302(dose 1); Intravitreal injection of IBI302(dose 2) and 2 more · For: Neovascular Age-related Macular Degeneration; Diabetic Macular Edema
Sites: Beijing, China
- A Study of IBI302 in Patients With nAMDPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04820452 · 231 participants · Start Apr 28, 2021 · Primary completion Jan 13, 2023
Drug: Low dose IBI302; High dose IBI302 and 1 more · For: Neovascular Age-related Macular Degeneration
Sites: Suzhou, China
- A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME)Pivotal-lookingActive, not recruiting
Innovent Biologics Technology Limited (Shanghai R&D Center)Industry
NCT06908876 · 150 participants · Start Apr 24, 2025 · Primary completion Dec 31, 2026
Drug: IBI302; IBI302 and 1 more · For: Diabetic Macular Oedema
Sites: Shanghai, China
- A Study of Longer Interval of IVT IBI302 in Subjects With nAMDPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05403749 · 132 participants · Start Jun 29, 2022 · Primary completion May 13, 2024
Drug: dose 1 IBI302; Aflibercept and 1 more · For: Neovascular Age-related Macular Degeneration
Sites: Shanghai, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT03814291 · 31 participants · Start Apr 15, 2019 · Primary completion Mar 5, 2020
Drug: IBI302; IBI302 and 4 more · For: Neovascular Age-related Macular Degeneration
Sites: Shanghai, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04370379 · 18 participants · Start May 28, 2020 · Primary completion Apr 30, 2021
Drug: IBI302 (the first dose level); IBI302 (the second dose level) and 1 more · For: Neovascular Age-related Macular Degeneration
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Emerging solutions for neovascular age-related macular degeneration.
Franco JJ, Wubben TJ · Curr Opin Ophthalmol 2026
- Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial.
Li T, Yang S, Liu Q, et al. · Ophthalmol Sci 2026
- Efdamrofusp alfa: an insight into the novel drug and its use in age-related macular degeneration.
Rath S, Ibrahim AA, Singh A, et al. · Int J Retina Vitreous 2025
- Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy.
Yang S, Li T, Jia H, et al. · Sci Transl Med 2022
- Protective Effect of a Bispecific Fc-Fusion Protein on the Barrier of Human Retinal Pigment Epithelial Cells.
Wang J, Wang Y, Yu D, et al. · Ophthalmic Res 2021
- IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys.
Ren X, Li J, Xu X, et al. · Exp Eye Res 2016
Also in development for Neovascular Age-related Macular Degeneration
- OTX-TKIaxitinib implantPhase 33 trials
Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)
- Surabgene LomparvovecABBV-RGX-314Phase 32 trials
AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration
- ABP 938Phase 31 trial
Amgen · Neovascular Age-related Macular Degeneration, nAMD
- ASKG712AM712, VIS-101Phase 21 trial
Visara, Inc. · Neovascular Age-related Macular Degeneration
- RRG001Phase 21 trial
Shanghai Refreshgene Technology Co., Ltd. · Neovascular Age-related Macular Degeneration
- SAR402663Phase 21 trial
Sanofi · Neovascular Age-related Macular Degeneration
- SYL1801Phase 21 trial
Sylentis, S.A. · Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.